Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.
Rockville, US
Size (employees)
20 (est)
Rexahn Pharmaceuticals was founded in 2001 and is headquartered in Rockville, US

Rexahn Pharmaceuticals Office Locations

Rexahn Pharmaceuticals has office in Rockville
Rockville, US

Rexahn Pharmaceuticals Metrics

Rexahn Pharmaceuticals Summary

Market capitalization

$100.9 m

Closing share price

Rexahn Pharmaceuticals's current market capitalization is $100.9 m.

Rexahn Pharmaceuticals Financials

We estimate that Rexahn Pharmaceuticals's revenue is $0 in 2015 which is a NaN% decrease from the previous period.
Y, 2015Y, 2016


Revenue growth, %


Rexahn Pharmaceuticals Market Value History

Rexahn Pharmaceuticals Company Life

You may also be interested in